Christopher Kurtz, MD, is a physician executive and clinical scientist specializing in cardiovascular biotechnology. With a robust background in cardiology, they served as Executive Medical Director and Global Development Lead for omecamtiv mecarbil at Amgen, where they managed pivotal studies and developed global product strategies. Their previous roles included Vice President of Global Development, overseeing therapeutic areas like Cardiovascular and Metabolic, and Chief Medical Officer at Kate Therapeutics. Christopher earned their Doctor of Medicine degree from Mayo Medical School after completing a fellowship in Cardiovascular Disease at the University of Washington School of Medicine.
This person is not in the org chart
This person is not in any teams
This person is not in any offices